Rare genetic disorders
We support innovative biotechs in Italy as they push promising research programs in rare genetic disorders towards preclinical and clinical development.
Our unique collaboration with the Telethon Foundation aims to bring Italian scientific excellence to the world stage. Our mission is to foster a thriving biotech ecosystem in Italy.
|2018||Sofinnova Telethon Fund||€108 million|
Fund: Sofinnova Telethon Fund
AMT: €108 million
“We come from the tech transfer world so we understand what it takes to build companies around the expertise at universities and institutions."
“There has to be more willingness to invest in the early stage. If nobody had invested in mRNA technology 10 years ago, I don't think we would have had the Covid vaccine in less than one year.”
Alia Therapeutics appoints Adel Nada as Independent Board Director
Alia Therapeutics names Letizia Goretti as Chief Executive Officer
PinCell announces 2 successful in-vivo studies for breakthrough skin disease therapy
Alia Therapeutics secures €4.4 million seed financing extension led by Sofinnova Partners
Chroma Medicine secures $135M in Series B financing to advance breakthrough epigenetic editing technology and expand pipeline of durable precision genomic medicines